Sun Pharmaceutical Industries is set to acquire Organon & Co. for $11.75 billion, a move that will significantly bolster its global presence and innovative medicines business. This strategic acquisition positions Sun Pharma as a top-tier player in women's health and biosimilars, aiming for substantial long-term value creation and a stronger diversified platform.